96965 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons; Interleukins [IL] IL-7
MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#2CELL SIGNALING COMPLEXES AND USES THEREOF
#3METHODS FOR REPROGRAMMING AND GENE EDITING CELLS
#4HUMANIZED IMMUNODEFICIENT MOUSE MODELS
#5IMMUNOCOMPETENT CELL AND EXPRESSION VECTOR EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION / A CELL SURFACE MOLECULE SPECIFICALLY RECOGNIZING HUMAN MESOTHELIN, IL-7 AND CCL19
#6SINGLE-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#7Methods of Treating Glioblastoma
#8Non-Signaling Chimeric Antigen Receptor Gamma Delta T-Cells
#9THERAPEUTIC CYTOKINES AND METHODS
#10CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS
#11New Interleukin-7 Immunoconjugates
#12PLURIPOTENT STEM CELL-DERIVED IMMUNE CELL INDUCING CHEMOTAXIS FOR HETEROGENEOUS IMMUNE CELLS
#13CHIMERIC ANTIGEN RECEPTOR, CELL EXPRESSING SAID RECEPTOR, PHARMACEUTICAL COMPOSITION INCLUDING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR INCLUDING NUCLEOTIDE SEQUENCE ENCODING SAID CHIMERIC ANTIGEN RECEPTOR
#14METHODS TO GENERATE ENHANCED TUMOR INFILTRATING LYMPHOCYTES THROUGH MICROFLUIDIC DELIVERY
#15EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY
#16ENHANCED ANTIGEN PRESENTING ABILITY OF CAR T CELLS BY CO-INTRODUCTION OF COSTIMULATORY MOLECULES
#17ISOLATED IMMUNE CELL EXPRESSING A RECEPTOR, INTERLEUKIN-7, AND CHEMOKINE (C-C MOTIF) LIGAND 19
#18FORMULATION OF MODIFIED INTERLEUKIN-7 FUSION PROTEIN
#19PHARMACEUTICAL COMPOSITION COMPRISING IMMUNOGLOBULIN FC-FUSED INTERLEUKIN-7 FUSION PROTEIN FOR PREVENTING OR TREATING HUMAN PAPILLOMAVIRUS-CAUSED DISEASES
#20CAR-EXPRESSING CELLS AGAINST MULTIPLE TUMOR ANTIGENS AND USES THEREOF
#21METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
#22TGF-Beta Polypeptides
#23ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents
#24BISPECIFIC ANTIBODY FUSION MOLECULES AND METHODS OF USE THEREOF
#25THERAPEUTIC NUCLEIC ACID MOLECULE, MIXTURE, AND DRUG, AND USE THEREOF IN TREATING SOLID TUMOR
#26METHODS AND COMPOSITIONS FOR CONTROLLING T CELL ACTIVATION
#27ANTI-EGFRviii ANTIBODY, POLYPEPTIDE, CELL CAPABLE OF EXPRESSING SAID POLYPEPTIDE, PHARMACEUTICAL COMPOSITION COMPRISING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR COMPRISING NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE
#28ALTERING CYTOKINE SPECIFICITY THROUGH BINDING VALENCY
#29MEMBRANE SURFACE PROTEIN CONTAINING GPI ANCHOR REGION
#30T Cell Modification and Use Thereof
#31ENGINEERED SAFETY IN CELL THERAPY
#32MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#33Cell signaling complexes and uses thereof
#34INTERLEUKIN 7 AND INTERLEUKIN 21 FUSION PROTEINS
#35NEW INTERLEUKIN-7 IMMUNOCONJUGATES
#36IL-7 POLYPEPTIDES, IMMUNOCYTOKINES COMPRISING SAME, AND USES THEREOF
#37Use Of Growth Factors For T Cell Activation
#38COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY
#39SENESCENCE TREATMENT with IL-15-BASED FUSIONS to IL-7 and IL-21
#40ENGINEERED IMMUNE CELL THAT SPECIFICALLY TARGETS MESOTHELIN AND USES THEREOF
#41ENGINEERED SOLUBLE DECOY RECEPTORS TO ENHANCE CANCER IMMUNOTHERAPY
#42THERAPEUTIC RNA FOR TREATING CANCER
#43CD99-targeting chimeric antigen receptor and application thereof
#44IMMUNOCOMPETENT CELL AND EXPRESSION VECTOR EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION, AND CHIMERIC ANTIGEN RECEPTOR
#45HUMANIZED ANTI-MUC1* ANTIBODIES AND DIRECT USE OF CLEAVAGE ENZYME
#46ALTERNATIVE PD1-IL7V IMMUNOCONJUGATES FOR THE TREATMENT OF CANCER
#47ENHANCER FOR T-CELLS OR B-CELLS HAVING MEMORY FUNCTION, MALIGNANT TUMOR RECURRENCE INHIBITOR, AND INDUCER FOR INDUCING MEMORY FUNCTION IN T-CELLS OR B-CELLS
#48ENGINEERED IMMUNE CELLS, COMPOSITIONS AND METHODS THEREOF
#49ATP-dependent agonists of immune cells function as anticancer agents
#50Immunocompetent Cell and Expression Vector Expressing Regulatory Factors of Immune Function
#51MULTISPECIFIC PROTEINS COMPRISING AN NKP46-BINDING SITE, A CANCER ANTGIENGE BINDING SITE FUSED TO A CYTOKINE FOR NK CELL ENGAGING
#52BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS
#53NEW SCAFFOLD FOR BIFUNCTIONAL MOLECULES WITH IMPROVED PROPERTIES
#54NOVEL RECOMBINANT STRAIN OF MYCOBACTERIUM SMEGMATIS AND USE OF SAME
#55SYNTHETIC IL-7 AND IL-7 IMMUNOCYTOKINES
#56IMMUNOCOMPETENT CELL THAT EXPRESSES A CELL SURFACE MOLECULE SPECIFICALLY RECOGNIZING HUMAN MESOTHELIN, IL-7 AND CCL19
#57MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#58MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
#59MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#60MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#61CHIMERIC ANTIGEN RECEPTOR FUSION PROTEIN CO-EXPRESSING IL-7 AND CCR2B, AND APPLICATION THEREOF
#62LINKER PEPTIDE FOR CONSTRUCTING FUSION PROTEIN
#63USE OF INTERLEUKIN-7 FOR THE TREATMENT OF CORONAVIRUS
#64USE OF IL-7R-ALPHA-GAMMA AGONIST PEPTIDES IN CELL MANUFACTURING
#65IL-7 FUSION PROTEIN AND RELATED METHODS
#66IL-15-BASED FUSIONS TO IL-7 AND IL-21
#67BIFUNCTIONAL ANTI-PD1/IL-7 MOLECULES
#68IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULES
#69TARGETED CYTOKINE CONSTRUCT FOR ENGINEERED CELL THERAPY
#70Anti-GPC3 antibody
#71PHARMACEUTICAL COMPOSITION COMPRISING IMMUNOGLOBULIN FC-FUSED INTERLEUKIN-7 FUSION PROTEIN FOR PREVENTING OR TREATING HUMAN PAPILLOMAVIRUS-CAUSED DISEASES
#72EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY
#73ENGINEERED IMMUNE CELL AND USE THEREOF
#74TGF-Beta Polypeptides
#75TRANSFORMED IMMUNE CELLS INDUCING CHEMOTAXIS TOWARDS HETEROGENEOUS IMMUNE CELLS
#76MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#77NOVEL RECOMBINANT VACCINIA VIRUS AND USE THEREOF
#78METHODS FOR SELECTIVELY MODULATING THE ACTIVITY OF DISTINCT SUBTYPES OF CELLS
#79ANTIBODY MOLECULES THAT BIND TO NKP30 AND USES THEREOF
#80Methods and compositions for transducing lymphocytes and regulating the activity thereof
#81NUCLEIC ACID CONSTRUCT, RECOMBINANT INFLUENZA VIRUS, METHOD FOR PREPARING A RECOMBINANT INFLUENZA VIRUS, COMPOSITION AND USE
#82IL-7Rαγc ligand immunoglobulin fusion proteins
#83BIFUNCTIONAL MOLECULES COMPRISING AN IL-7 VARIANT
#84FORMULATION OF MODIFIED INTERLEUKIN-7 FUSION PROTEIN
#85MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#86Recombinant Viral Vector, Immunogenic Composition Comprising Same, and Uses
#87METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
#88COLLAGEN-TARGETED FUSION PROTEINS AND ANTIBODIES
#89Methods and Compositions for the Reduction of Chimeric Antigen Receptor Tonic Signaling
#90CYTOKINE COMBINATION
#91IMMUNOCONJUGATES
#92ENGINEERED OPTIMIZED CYTOKINE COMPOSITIONS
#93GLYPICAN-2-BINDING MOIETIES, CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#94MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#95NOVEL MASKED CYTOKINES AND METHODS OF USE THEREOF
#96MULTIFUNCTIONAL MOLECULES THAT BIND TO CD33 AND USES THEREOF
#97ANAPLASTIC LYMPHOMA KINASE CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
#98BIFUNCTIONAL ANTI-PD-1/IL-7 MOLECULE
#99ANTI-GPC3 SINGLE-CHAIN ANTIBODY-CONTAINING CAR
#100COMPOSITIONS AND METHODS OF USE OF ONCOLYTIC VIRUS LIKE VESICLES
#101MODULATING GAMMA-C-CYTOKINE ACTIVITY
#102Methods of Treating Glioblastoma
#103Drug for Treating Cancer, Combination Drug, Drug Composition, Immune Responsive Cell, Nucleic Acid Delivery Vehicle, and Product
#104TGF-β polypeptides
#105METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES TO EXPRESS POLYPEPTIDES COMPRISING THE INTRACELLULAR DOMAIN OF CD79A AND CD79B
#106T CELL RECEPTORS AND METHODS OF USE THEREOF
#107T CELL RECEPTORS AND METHODS OF USE THEREOF
#108Immunocompetent cell and expression vector expressing regulatory factors of immune function
#109SYNTHETIC IMMUNE CELLS AND METHODS OF USE THEREOF
#110THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCER IN COMBINATION WITH ANALOGS OF INTERLEUKIN PROTEINS
#111PROTEIN MOLECULE AND USE THEREOF
#112ARTIFICIAL IMMUNOSURVEILLANCE CHIMERIC ANTIGEN RECEPTOR (AI-CAR) AND CELLS EXPRESSING THE SAME
#113CYTOKINE COCKTAILS FOR SELECTIVE EXPANSION OF T CELL SUBSETS
#114TREATMENT INVOLVING CAR-ENGINEERED T CELLS AND CYTOKINES
#115ADVANCED CHIMERIC ANTIGEN RECEPTOR VECTORS FOR TARGETING SOLID TUMORS
#116BIFUNCTIONAL MOLECULES WITH IL-7 ACTIVITY
#117Linker peptide for constructing fusion protein
#118CHIMERIC CYTOKINE RECEPTORS
#119CAR-EXPRESSING CELLS AGAINST MULTIPLE TUMOR ANTIGENS AND USES THEREOF
#120T cell modification and use thereof
#121METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND USE THEREOF
#122IL-15-based fusions to IL-7 and IL-21
#123METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
#124Protein heterodimer and use thereof
#125IMMUNOMODULATORY ONCOLYTIC ADENOVIRAL VECTORS, AND METHODS OF PRODUCTION AND USE THEREOF FOR TREATMENT OF CANCER
#126MODIFIED INTERLEUKIN-7 PROTEINS AND USES THEREOF
#127Enhanced antigen presenting ability of RNA car T cells by co-introduction of costimulatory molecules
#128MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#129USE OF INTERLEUKIN-7 AND CHIMERIC ANTIGEN RECEPTOR (CAR)-BEARING IMMUNE EFFECTOR CELLS FOR TREATING TUMOR
#130Compositions and methods for targeted cytokine delivery
#131CAR EXPRESSION VECTOR AND CAR-EXPRESSING T CELLS
#132Engineered safety in cell therapy
#133GENETICALLY ENGINEERED CELL AND APPLICATION THEREOF
#134SUBSETS OF HUMAN NATURAL KILLER CELLS WITH ENHANCED ANTIBODY-DIRECTED IMMUNE RESPONSES
#135CELL SORTING SYSTEMS AND METHODS OF USE
#136CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER
#137Generating HPV antigen-specific cells from a naive T cell population
#138Bakers's yeast expressing anti-staling/freshness amylases
#139Generating HPV antigen-specific cells from a naive T cell population
#140Multi-chain chimeric polypeptides and uses thereof
#141CHIMERIC ANTIGEN RECEPTOR
#142TARGETING STAT SUMOYLATION TO ENHANCE IMMUNE RESPONSES
#143TREATMENT USING CYTOKINE ENCODING RNA
#144Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
#145Methods to Determine the Presence of an Antibody that Binds Modified Human Thymic Stromal Lymphopoietin (TSLP)
#146Engineered Optimized Cytokine Compositions
#147Peptide hydrogels and use thereof
#148IN VIVO PRODUCTION OF PROTEINS
#149Multi-chain chimeric polypeptides and uses thereof
#150Multi-chain chimeric polypeptides and uses thereof
#151IL-7-FC-fusion proteins
#152METHOD AND SYSTEM FOR SCREENING ANTI-TUMOUR SUBSTANCES
#153Cytokine fusion proteins
#154Exosomes for immuno-oncology and anti-inflammatory therapy
#155METHODS FOR PRODUCING LYMPHOCYTE PROGENITORS
#156METHODS AND COMPOSITIONS FOR TRANSDUCING AND EXPANDING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
#157HUMANIZED ANTI-MUC1* ANTIBODIES AND DIRECT USE OF CLEAVAGE ENZYME
#158NOVEL GENETICALLY ENGINEERED VACCINIA VIRUSES
#159Expression of metabolic modulators in tumor microenvironment to improve tumor therapy
#160IMMUNOCOMPETENT CELL THAT EXPRESSES A CELL SURFACE MOLECULE SPECIFICALLY RECOGNIZING HUMAN MESOTHELIN, IL-7 AND CCL19
#161Cytokine combination
#162Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#163Multi-chain chimeric polypeptides and uses thereof
#164MULTI-FUNCTION AND MULTI-TARGETING CAR SYSTEM AND METHODS FOR USE THEREOF
#165Anti-GPC3 antibody
#166Anti-GPC3 antibody
#167Anti-PD-L1 antibody and IL-7 fusions
#168HUMANIZED IL-7 RODENTS
#169CAR expression vector and CAR-expressing T cells
#170In vivo production of proteins
#171IL-15-based fusions to IL-7 and IL-21
#172CONJUGATES OF AN IL-7 MOIETY AND A POLYMER
#173CYSTEINE VARIANTS OF INTERLEUKIN-11 AND METHODS OF USE THEREOF
#174ARTIFICIAL ANTIGEN PRESENTING CELLS FOR EXPANDING IMMUNE CELLS FOR IMMUNOTHERAPY
#175Exosomes for immuno-oncology and anti-inflammatory therapy
#176Linker peptide for constructing fusion protein
#177Nipah virus envelope glycoprotein pseudotyped lentivirus
#178Immunomodulatory Oncolytic Adenoviral Vectors, and Methods of Production and Use Thereof for Treatment of Cancer
#179Compositions and methods for targeted cytokine delivery
#180Modified interleukin-7 protein
#181T cell modification and use thereof
#182Immunocompetent cell and expression vector expressing regulatory factors of immune function
#183Modulating gamma-c-cytokine activity
#184Humanized IL-7 rodents
#185Formulation of modified interleukin-7 fusion protein
#186Pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases
#187Generating HPV antigen-specific cells from a naive T cell population
#188Modified Polynucleotides for the production of biologics and proteins associated with human disease
#189Conjugates of GM-CSF and IL-7, and Compositions Thereof
#190Modified interleukin-7 protein
#191Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
#192Car-expressing cells against multiple tumor antigens and uses thereof
#193Method to increase the number of circulating platelets by administering PEGylated cysteine variants of IL-11
#194Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#195In vivo production of proteins
#196Genetically engineered vaccinia viruses
#197Method for treatment of metastatic and refractory cancers and tumors with an inducer that overcomes inhibition of T cell proliferation
#198Humanized IL-7 rodents
#199Methods and compositions for transducing lymphocytes and regulated expansion thereof
#200Car expression vector and car-expressing T cells
#201Modulators of gamma-C-cytokine activity
#202Modified interleukin-7 protein
#203Modulating gamma-C-cytokine activity
#204Humanized IL-7 rodents
#205Method for treatment of metastatic and refractory cancers and tumors with an inducer that overcomes inhibition of T cell proliferation
#206Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
#207Uses of conjugates of GM-CSF and IL-7 to treat viral infections
#208Process for Generating Synthetic Engineered Recombinant Proteins for Vaccination, Diagnosis and Treatment of Disease
#209Modulation of γδ T cells
#210Modified polynucleotides for the production of biologics and proteins associated with human disease
#211HUMANIZED IL-7 RODENTS
#212PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT INCLUDING FUSION PROTEIN
#213Humanized IL-7 rodents
#214Antibodies that inhibit TSLP activity
#215Conjugates of GM-CSF and IL-7, compositions and methods related thereto
#216DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
#217Nucleic acids encoding modified human thymic stromal lymphopoietin
#218Humanized IL-7 rodents
#219Compositions comprising IL-7 receptor ligands
#220Modified human thymic stromal lymphopoietin
#221Hyperglycosylated mammalian IL-7 IgG conjugate composition
#222Antibodies that inhibit TSLP activity
#223Cysteine variants of interferon gamma
#224IL-7 fusion proteins
#225MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN
#226USES OF MAMMALIAN CYTOKINE; RELATED REAGENTS
#227Nucleic acids encoding a chimeric polypeptide comprising IL-7 and HGF-beta chain and methods of use
#228Fusion proteins comprising canine thymic stromal lymphopoietin protein and uses thereof
#229ANTIBODIES THAT INHIBIT TSLP ACTIVITY
#230Viral particles encoding multifunctional cytokines
#231Hyperglycosylated IL-7, preparation and uses
#232Nucleic acid encoding modified human thymic stromal lymphopoietin
#233USES OF MAMMALIAN CYTOKINE; RELATED REAGENTS
#234Multifunctional Cytokines
#235TSLP VACCINE FOR THE TREATMENT OF TH2 MEDIATED INFLAMMATORY CONDITIONS
#236Thymic stromal lymphpoietin promoter and use therefor
#237DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
#238Antibodies that inhibit TSLP activity
#239USES OF MAMMALIAN CYTOKINE: RELATED REAGENTS
#240IL-7 fusion proteins
#241Cysteine variants of interferon gamma
#242Cysteine variants of interferon-gamma
#243Glycosylated IL-7, preparation and uses
#244Canine thymic stromal lymphopoietin protein and uses thereof
#245Modified human thymic stromal lymphopoietin
#246Methods for use of TSLP and agonists and antagonists thereof
#247Modified human thymic stromal lymphopoietin
#248Chimeric cytokine of IL-7 and beta-chain of HGF and methods of use
#249Multifunctional cytokines
#250Uses of mammalian cytokine: related reagents
#251Human TSLP polynucleotides
#252Gene expression using metal ion dependent repressor/operator tandems
#253IL-7 variants with reduced immunogenicity
#254Modified dendritic cells
#255Methods for use of TSLP and agonists and antagonists thereof
#256IL-7 drug substance, composition, preparation and uses
#257Cysteine substitution variants of beta interferon
#258COOH-terminally added cysteine variant of the beta interferon
#259IL-7 fusion proteins
#260Cysteine variants of erythropoietin
#261Cysteine variants of erythropoietin
#262Multifunctional cytokines
#263Interleukin-7 molecules with altered biological properties